주인공 치료학, Inc.
US ˙ NasdaqGM ˙ US74366E1029

SecurityPTGX / Protagonist Therapeutics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership1,018,222 shares
Latest Disclosed Value $ 107,320,718
Morgan Stanley reports 15.84% increase in ownership of PTGX / Protagonist Therapeutics, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 1,018,222 shares of Protagonist Therapeutics, Inc. (US:PTGX) valued at $107,320,599 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 879,024 shares of Protagonist Therapeutics, Inc.. This represents a change in shares of 15.84% during the quarter. The current value of the position is $99,154,458 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,018,222 139,198 15.84 107,321 39.79 0.0065
2026-05-27 2025-12-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 879,024 110,665 14.40 76,774 50.41 0.0046
2026-02-13 2025-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 879,024 110,665 76,774 0.0046
2026-05-27 2025-09-30 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 768,359 -100,604 -11.58 51,042 6.28 0.0031
2025-11-14 2025-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 768,359 -100,604 51,042 0.0031
2025-08-15 2025-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 868,963 371,858 74.80 48,028 99.78 0.0031
2025-05-15 2025-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 497,105 -43,210 -8.00 24,040 15.27 0.0017
2025-05-15 2024-12-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 540,315 -88,308 -14.05 20,856 -26.27 0.0015
2025-02-14 2024-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 540,315 -88,308 20,856 0.0015
2025-05-14 2024-09-30 13F/A-2 PROTAGONIST THERAPEUTICS COM 74366E102 628,623 283,330 82.05 28,288 136.44 0.0021
2025-02-14 2024-09-30 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 628,623 283,330 28,288 0.0021
2024-11-14 2024-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 628,623 283,330 28,288 0.0002
2025-05-14 2024-06-30 13F/A-2 PROTAGONIST THERAPEUTICS COM 74366E102 345,293 -1,534,585 -81.63 11,964 -78.00 0.0009
2024-10-17 2024-06-30 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 345,293 -1,534,585 11,964 0.0009
2024-08-14 2024-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 345,293 -1,534,585 11,964 0.0009
2024-10-17 2024-03-31 13F/A-2 PROTAGONIST THERAPEUTICS COM 74366E102 1,879,878 688,041 57.73 54,385 99.00 0.0044
2024-08-16 2024-03-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 1,879,878 688,041 54,385 0.0005
2024-05-15 2024-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,879,878 688,041 54,385 0.0044
2024-08-16 2023-12-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 1,191,837 762,833 177.81 27,329 281.94 0.0024
2024-02-13 2023-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,191,837 762,833 27,329 0.0024
2023-11-15 2023-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 429,004 -149,017 -25.78 7,156 -55.18 0.0007
2023-08-14 2023-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 578,021 -992,489 -63.20 15,965 -55.80 0.0016
2023-05-15 2023-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,570,510 -868,007 -35.60 36,122 35.77 0.0039
2023-02-14 2022-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 2,438,517 210,942 9.47 26,604 41.68 0.0030
2022-11-14 2022-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 2,227,575 451,123 25.39 18,777 33.64 0.0026
2022-10-27 2022-06-30 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 1,776,452 439,349 32.86 14,050 -55.62 0.0018
2022-08-15 2022-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,776,452 439,349 14,050 0.0004
2022-10-27 2022-03-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 1,337,103 1,229,687 1,144.79 31,661 761.76 0.0043
2022-05-13 2022-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,337,103 1,229,687 31,661 0.0043
2022-02-14 2021-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 107,416 -366,899 -77.35 3,674 -56.29 0.0005
2021-11-15 2021-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 474,315 404,485 579.24 8,405 168.27 0.0011
2021-08-23 2021-06-30 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 69,830 65,107 1,378.51 3,133 2,447.15 0.0004
2021-08-16 2021-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 69,830 65,107 3,133 0.0001
2021-05-17 2021-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 4,723 -28,766 -85.90 123 -81.78 0.0000
2021-02-16 2020-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 33,489 25,544 321.51 675 332.69 0.0001
2020-11-13 2020-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 7,945 -2,833 -26.29 156 -17.89 0.0000
2020-08-14 2020-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 10,778 9,415 690.76 190 1,800.00 0.0000
2020-05-26 2020-03-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 1,363 -31,966 -95.91 10 -95.74 0.0000
2020-05-15 2020-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,363 -31,966 10 0.7682
2020-02-14 2019-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 33,329 -88,674 -72.68 235 -83.96 0.0001
2019-11-14 2019-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 122,003 121,347 18,498.02 1,465 18,212.50 0.0004
2019-08-14 2019-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 656 -3,831 -85.38 8 -85.96 0.0000
2019-05-15 2019-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 4,487 54 1.22 57 90.00 0.0000
2019-02-14 2018-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 4,433 -18,204 -80.42 30 -87.12 0.0000
2019-04-23 2018-09-30 13F/A-2 PROTAGONIST THERAPEUTICS COM 74366E102 22,637 -23,043 -50.44 233 -24.35 0.0001
2018-11-20 2018-09-30 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 22,637 0 233 0.0001
2018-11-14 2018-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 22,637 -23,043 233
2019-04-23 2018-06-30 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 45,680 17,503 62.12 308 27.27 0.0001
2018-08-14 2018-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 45,680 17,503 308
2019-04-23 2018-03-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 28,177 593 2.15 242 -57.84 0.0001
2018-05-14 2018-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 28,177 593 242
2019-04-23 2017-12-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 27,584 8,303 43.06 574 68.33 0.0002
2018-02-14 2017-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 27,584 8,303 574
2017-11-14 2017-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 19,281 10,904 130.17 341 258.95 0.0001
2017-08-11 2017-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 8,377 -1,524 -15.39 95 -25.20 0.0000
2017-05-22 2017-03-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 9,901 -12,877 -56.53 127 -74.65 0.0000
2017-05-12 2017-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 9,901 127
2017-02-22 2016-12-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 22,778 22,578 11,289.00 501 12,425.00 0.0002
2017-02-13 2016-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 22,778 501
2016-11-10 2016-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 200 200 4 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.